Testosterone Therapy Replacement Multi-District Litigation

Brian News

Bahe Cook Cantley & Nefzger is currently offering free case evaluations to men who may have suffered cardiac problems due to their use of testosterone therapy medications, such as AndroGel.

More than 2,200 cases have been filed on behalf of men who have suffered heart attacks, strokes, and other cardiovascular complications after using testosterone replacement medications. These cases are currently pending in a Multi-District litigation in the U.S. District Court for the Northern District of Illinois against both manufacturers and distributors of the Low-T drugs. The lawsuits allege strict liability for design defects and failure to properly warn consumers, as well as negligence, breach of warranty, fraud, and unjust enrichment, among other things.

On March 3, 2015 the U.S. Food & Drug Administration ordered manufacturers of prescription Low-Testosterone medications to modify their labeling practices in two ways. First, the labels must include a warning of the association between using testosterone replacement therapy and an increased risk of heart attack and stroke. Second, the labels must clearly state that the drugs have not been proven safe or effective for treating low testosterone levels in aging men.

Men who allegedly suffered heart attacks, strokes, deep vein thrombosis, pulmonary embolism or other serious cardiovascular events after using low testosterone replacement drugs may be entitled to compensation for medical bills, lost wages and other damages related to their injuries.

Some of the more popular testosterone therapy medications include Androgel®, Androderm®, Fortesta®, Axiron®, Testim®, Delatestryl®, Depo-Testosterone®, Striant®, Testopel®, and others. If you or someone you know are using any of these drugs, take caution. It is also important to be wary of the generic versions of these products.

Our firm is currently investigating and accepting these cases.